Doyle L Austin相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study

更正：LTBK-01。AZD6244（Selumetinib）治疗复发或难治性儿童低级别胶质瘤的II期及再治疗研究的最新进展：一项儿童脑肿瘤联盟（PBTC）研究

期刊:Neuro-Oncology

影响因子:13.4

doi:10.1093/neuonc/noac029

Fangusaro, Jason R; Onar-Thomas, Arzu; Poussaint, Tina Young; Wu, Shengjie; Ligon, Azra H; Lindeman, Neal Ian; Banerjee, Anuradha; Packer, Roger; Kilburn, Lindsay B; Pollack, Ian F; Qaddoumi, Ibrahim A; Fisher, Paul Graham; Dhall, Girish; Baxter, Patricia Ann; Kreissman, Susan G; Doyle, L Austin; Smith, Malcolm A; Fouladi, Maryam; Dunkel, Ira J

发表日期：2022

文献求助收藏

Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies

一项针对晚期实体恶性肿瘤患者的 I 期研究，评估了口服 VEGFR 抑制剂 cediranib 与口服 MEK 抑制剂 selumetinib 联合用药的疗效。

期刊:Investigational New Drugs

影响因子:2.7

doi:10.1007/s10637-021-01175-6

Hubbard, Joleen M; Yin, Jun; Schenk, Erin L; Qin, Rui; Reid, Joel M; Strand, Carrie; Fiskum, Jack; Menefee, Michael; Lin, Grace; Doyle, L Austin; Ivy, Percy; Erlichman, Charles; Adjei, Alex; Haluska, Paul; Costello, Brian A

发表日期：2022

文献求助收藏

Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial

Capivasertib 对 AKT1 E17K 突变肿瘤患者的疗效：NCI-MATCH 子方案 EAY131-Y 非随机试验

期刊:Jama Oncology

影响因子:20.1

doi:10.1001/jamaoncol.2020.6741

Kalinsky, Kevin; Hong, Fangxin; McCourt, Carolyn K; Sachdev, Jasgit C; Mitchell, Edith P; Zwiebel, James A; Doyle, L Austin; McShane, Lisa M; Li, Shuli; Gray, Robert J; Rubinstein, Larry V; Patton, David; Williams, Paul M; Hamilton, Stanley R; Conley, Barbara A; O'Dwyer, Peter J; Harris, Lyndsay N; Arteaga, Carlos L; Chen, Alice P; Flaherty, Keith T

发表日期：2021

文献求助收藏

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

在铂类耐药的高级别浆液性卵巢癌中，贝佐塞替联合吉西他滨与单用吉西他滨的疗效比较：一项多中心、开放标签、随机、II期试验

期刊:Lancet Oncology

影响因子:35.9

doi:10.1016/S1470-2045(20)30180-7

Konstantinopoulos, Panagiotis A; Cheng, Su-Chun; Wahner Hendrickson, Andrea E; Penson, Richard T; Schumer, Susan T; Doyle, L Austin; Lee, Elizabeth K; Kohn, Elise C; Duska, Linda R; Crispens, Marta A; Olawaiye, Alexander B; Winer, Ira S; Barroilhet, Lisa M; Fu, Siqing; McHale, Michael T; Schilder, Russell J; Färkkilä, Anniina; Chowdhury, Dipanjan; Curtis, Jennifer; Quinn, Roxanne S; Bowes, Brittany; D'Andrea, Alan D; Shapiro, Geoffrey I; Matulonis, Ursula A

发表日期：2020

文献求助收藏

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

AKT抑制剂MK-2206治疗复发性铂耐药性高级别浆液性卵巢癌、输卵管癌或原发性腹膜癌的简化II期研究结果（NCT 01283035）

期刊:Gynecologic Oncology Reports

影响因子:1.3

doi:10.1016/j.gore.2020.100546

Lee, Elizabeth K; Tan-Wasielewski, Zhenying; Aghajanian, Carol; Coleman, Robert L; Curtis, Jennifer; Hirsch, Michelle S; Matulonis, Ursula A; Cantley, Lewis C; Mills, Gordon B; Doyle, L Austin; Liu, Joyce F

发表日期：2020

文献求助收藏

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

AKT抑制剂MK-2206在伴有PIK3CA或AKT突变和/或PTEN缺失/PTEN突变的晚期乳腺癌患者中进行的II期临床试验

期刊:Breast Cancer Research

影响因子:5.6

doi:10.1186/s13058-019-1154-8

Xing, Yan; Lin, Nancy U; Maurer, Matthew A; Chen, Huiqin; Mahvash, Armeen; Sahin, Aysegul; Akcakanat, Argun; Li, Yisheng; Abramson, Vandana; Litton, Jennifer; Chavez-MacGregor, Mariana; Valero, Vicente; Piha-Paul, Sarina A; Hong, David; Do, Kim-Anh; Tarco, Emily; Riall, Dianna; Eterovic, Agda Karina; Wulf, Gerburg M; Cantley, Lewis C; Mills, Gordon B; Doyle, L Austin; Winer, Eric; Hortobagyi, Gabriel N; Gonzalez-Angulo, Ana Maria; Meric-Bernstam, Funda

发表日期：2019

文献求助收藏

Final results of a randomized multicenter phase II study of alvocidib, cytarabine, and mitoxantrone versus cytarabine and daunorubicin (7 + 3) in newly diagnosed high-risk acute myeloid leukemia (AML)

一项随机多中心 II 期研究的最终结果，比较了阿洛西地、阿糖胞苷和米托蒽醌与阿糖胞苷和柔红霉素 (7 + 3) 治疗新诊断的高危急性髓系白血病 (AML) 的疗效。

期刊:Leukemia Research

影响因子:2.2

doi:10.1016/j.leukres.2018.08.005

Zeidner, Joshua F; Foster, Matthew C; Blackford, Amanda L; Litzow, Mark R; Morris, Lawrence E; Strickland, Stephen A; Lancet, Jeffrey E; Bose, Prithviraj; Levy, M Yair; Tibes, Raoul; Gojo, Ivana; Gocke, Christopher D; Rosner, Gary L; Little, Richard F; Wright, John J; Doyle, L Austin; Smith, B Douglas; Karp, Judith E

发表日期：2018

文献求助收藏

Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial

Selumetinib 和 MK-2206 与奥沙利铂和氟尿嘧啶治疗既往接受过治疗的转移性胰腺癌患者的疗效比较：SWOG S1115 研究随机临床试验

期刊:Jama Oncology

影响因子:20.1

doi:10.1001/jamaoncol.2016.5383

Chung, Vincent; McDonough, Shannon; Philip, Philip A; Cardin, Dana; Wang-Gillam, Andrea; Hui, Laifong; Tejani, Mohamedtaki A; Seery, Tara E; Dy, Irene A; Al Baghdadi, Tareq; Hendifar, Andrew E; Doyle, L Austin; Lowy, Andrew M; Guthrie, Katherine A; Blanke, Charles D; Hochster, Howard S

发表日期：2017

文献求助收藏

Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia

一项随机II期临床试验，比较阿糖胞苷联合或不联合CHK1抑制剂MK-8776治疗复发难治性急性髓系白血病的疗效。

期刊:Leukemia Research

影响因子:2.2

doi:10.1016/j.leukres.2017.09.005

Webster, Jonathan A; Tibes, Raoul; Morris, Larry; Blackford, Amanda L; Litzow, Mark; Patnaik, Mrinal; Rosner, Gary L; Gojo, Ivana; Kinders, Robert; Wang, Lihua; Doyle, L Austin; Huntoon, Catherine J; Karnitz, Larry M; Kaufmann, Scott H; Karp, Judith E; Smith, B Douglas

发表日期：2017

文献求助收藏

Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia

一项随机多中心 II 期研究，比较 flavopiridol（alvocidib）、阿糖胞苷和米托蒽醌 (FLAM) 与阿糖胞苷/柔红霉素 (7+3) 方案治疗新诊断的急性髓系白血病的疗效。

期刊:Haematologica

影响因子:7.9

doi:10.3324/haematol.2015.125849

Zeidner, Joshua F; Foster, Matthew C; Blackford, Amanda L; Litzow, Mark R; Morris, Lawrence E; Strickland, Stephen A; Lancet, Jeffrey E; Bose, Prithviraj; Levy, M Yair; Tibes, Raoul; Gojo, Ivana; Gocke, Christopher D; Rosner, Gary L; Little, Richard F; Wright, John J; Doyle, L Austin; Smith, B Douglas; Karp, Judith E

发表日期：2015

文献求助收藏